Eletriptan drug interactions: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Eletriptan}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERI...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Drug Interactions== | ||
====7.1 Ergot-Containing Drugs Including Other 5-HT1B/1D Agonists==== | |||
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine [DHE] or methysergide) and RELPAX within 24 hours of each other is contraindicated. Concomitant use of other 5-HT1 agonists within 24 hours of RELPAX treatment is contraindicated [seeContraindications (4)]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c | publisher = | date = | accessdate = }}</ref> | ====7.2 CYP3A4 Inhibitors==== | ||
Potent CYP3A4 inhibitors significantly increase the exposure of RELPAX. Relpax should not be used within at least 72 hours of treatment with potent CYP3A4 inhibitors [see Contraindications (4) and Clinical Pharmacology (12.3)]. | |||
====7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome==== | |||
Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [seeWarnings and Precautions (5.7)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== |
Latest revision as of 07:50, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Drug Interactions
7.1 Ergot-Containing Drugs Including Other 5-HT1B/1D Agonists
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine [DHE] or methysergide) and RELPAX within 24 hours of each other is contraindicated. Concomitant use of other 5-HT1 agonists within 24 hours of RELPAX treatment is contraindicated [seeContraindications (4)].
7.2 CYP3A4 Inhibitors
Potent CYP3A4 inhibitors significantly increase the exposure of RELPAX. Relpax should not be used within at least 72 hours of treatment with potent CYP3A4 inhibitors [see Contraindications (4) and Clinical Pharmacology (12.3)].
7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome
Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [seeWarnings and Precautions (5.7)].[1]
References
Adapted from the FDA Package Insert.